Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study.

Cancers (Basel) · 2020 · PMC7409289 · PMID 32698355

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the KEYNOTE-240 trial, although pembrolizumab in a second-line setting after prior sorafenib therapy improved OS (HR, 0.78; 95% CI, 0.61–1.00; one-sided p = 0.024) and PFS (HR, 0.72; 95% CI, 0.57–0.90; one-sided p = 0.002) compared to placebo, the outcomes did not reach statistical significance per specified criteria [ 18 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.